Get our Free Drug Patent Expiration Updates

Serving hundreds of leading biopharmaceutical companies globally:

US Army
Fuji
Daiichi Sankyo
AstraZeneca
Julphar
US Department of Justice
Express Scripts
Argus Health
Teva

Generated: November 14, 2018

DrugPatentWatch Database Preview

Details for New Drug Application (NDA): 020067

« Back to Dashboard

NDA 020067 describes EC-NAPROSYN, which is a drug marketed by Atnahs Pharma Us and is included in one NDA. It is available from four suppliers. Additional details are available on the EC-NAPROSYN profile page.

The generic ingredient in EC-NAPROSYN is naproxen. There are forty-two drug master file entries for this compound. Seventy-four suppliers are listed for this compound. Additional details are available on the naproxen profile page.
Summary for 020067
Tradename:EC-NAPROSYN
Applicant:Atnahs Pharma Us
Ingredient:naproxen
Patents:0
Formulation / Manufacturing:see details
Pharmacology for NDA: 020067
Medical Subject Heading (MeSH) Categories for 020067
Suppliers and Packaging for NDA: 020067
Tradename Generic Name Dosage NDA Application Type Supplier National Drug Code Package Code Package
EC-NAPROSYN naproxen TABLET, DELAYED RELEASE;ORAL 020067 NDA Genentech, Inc. 0004-6415 0004-6415-01 100 TABLET, DELAYED RELEASE in 1 BOTTLE, PLASTIC (0004-6415-01)
EC-NAPROSYN naproxen TABLET, DELAYED RELEASE;ORAL 020067 NDA Cameron Pharmaceuticals, LLC 42494-407 42494-407-01 100 TABLET, DELAYED RELEASE in 1 BOTTLE, PLASTIC (42494-407-01)

Profile for product number 002

Active Rx/OTC/Discontinued:RXDosage:TABLET, DELAYED RELEASE;ORALStrength375MG
Approval Date:Oct 14, 1994TE:ABRLD:Yes

Profile for product number 003

Active Rx/OTC/Discontinued:RXDosage:TABLET, DELAYED RELEASE;ORALStrength500MG
Approval Date:Oct 14, 1994TE:ABRLD:Yes

Complete Access Available with Subscription

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Argus Health
Harvard Business School
Cantor Fitzgerald
QuintilesIMS
Cerilliant
Express Scripts
Johnson and Johnson
Cipla
Colorcon

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.